Receipt date: 05/26/200 MAY 2 6 2005 Approx Les through 07.31/2006.048 (805).003

U.S. Patert and Trademark Office; U.S. DEPARTMENT OF COMMERCE
On Act of 1995, no persons are required to respond to a collection of information unities it contains a valid OMB control number.

Complete if Known PTO/SB/08B (08-03) Under the Paperwork Red Substitute for form PAASE Application Number 10/520.016 INFORMATION DISCLOSURE Filing Date 12/29/2004 STATEMENT BY APPLICANT First Named Inventor Okada, Hidechika Art Unit (Use as many sheets as necessary) Examiner Name

Attorney Docket Number

3348/2

Sheet

1

of 1

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1			
	1	OKADA et al., "Tosa Kogen GM2 ni Taisuru Hito-gata IgM Kotai no Ko-HIV Kassei", Nagova Shiritsu Daigaku Igakukai Zasshi, 1999, Vol. 50, No. 172, pg. 9-13		
	2	XIAOSHAN et al., "The IgM antibody level against ganglioside 6M2 correlates to the disease status of HIV-1-infected partieuts" Microbiology & Immunology 2000, Vol. 44, No. 5, pg. 4. 05 - 4.10		
	3	OKADA et al., "Human IgM monoclonal antibody to genglioside GM2 and complement suppress virus propagation in extreme cultures of tymophocytes from HIV-1 infected patients, 2 MILTON 1010gy 3 MILTON 1010gy 3 MILTON 1010gy 3	3 – 7	
		ASAI et al., "HIVA Kansen Saibo ni Hanno suru IgM Kotai no Hotal Kasseikand to amino-san Hairetsu and Kanrenser", Hotai Symp Nihon Seetial Bogyo Gakkai Godo Gakujutsu Shokai KoertiShu 2002, VOI. 3, NOS. 3–9, pg. 35		
		Duplicates		
		·		

Examiner	Date	
Signature	Considered	ĺ

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicated.

Applicant's under cultation designation number (optional, 2. Applicant is to place a check mark here if English language Transistion is attached.

Applicant's under cultation designation number (optional, 2. Applicant is to place a check mark here if English language Transistion is office (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFT of the view ray depending upon the includical case. Any application, and submitting the completed application from the tell SYTO. Time with very depending upon the includical case. Any amounted on the amount of lane you require to complete the form and/or suggestions for reducing this burden, should be sent to the Crief Information Officer, U.S. Patient and Trademark Officer, 20, Bost 1953, Assention, V.Z. 23311-4450. DON OTSENOR PEES OR COMPLETED FORMS TO THIS ADDRESS. SENTENDED. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.